BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
- VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
- The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
- The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
- The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.